A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects With Type 2 Diabetes Mellitus and Renal Impairment

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03550378

Enrollment

Registered

2018-06-08

Start date

2018-06-29

Completion date

2019-02-04

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Insufficiency, Type II Diabetes Mellitus

Keywords

Type 2 Diabetes Mellitus, MEDI0382, Renal Impairment, Glucose concentration, Hemoglobin A1c

Brief summary

A study to look at the effect MEDI0382 has on blood sugar in people with type 2 diabetes and kidney problems and also to check that MEDI0382 is well tolerated.

Interventions

DRUGMEDI0382

Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.

DRUGPlacebo

Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Intervention model description

Randomised, Double-Blind, Placebo-Controlled

Eligibility

Sex/Gender

ALL

Age

18 Years to 84 Years

Healthy volunteers

Inclusion criteria

1. Age ≥ 18 and \< 85 years at screening. 2. Signed and dated written informed consent (with the exception of consent for genetic and nongenetic research) prior to performing any protocol-related procedures, including screening evaluations. 3. Diagnosed with type 2 diabetes mellitus (T2DM) with glucose control managed with any insulin and/or oral therapy combination where no significant dose changes of oral therapy of more than 50% have occurred in the 3 months prior to screening 4. Body mass index (BMI) between 25 and 45 kg/m\^2 (inclusive) at screening 5. Haemoglobin A1c (HbA1c) range of 6.5 % to 10.5% (inclusive) at screening 6. Renal impairment with estimated glomerular filtration rate (eGFR) ≥ 30 and \< 60 mL/min/1.73 m\^2 at screening. Approximately 16 participants (40%) are required to have a screening eGFR ≥30 and \< 45 mL/min/1.73 m\^2 and at least 16 participants (40%) are required to have screening eGFR ≥45 and \< 60 mL/min/1.73 m\^2. 7. Females of childbearing potential must have a negative pregnancy test at screening and randomisation, and must not be lactating. Women of childbearing potential who are sexually active with a non-sterilized male partner must be using at least one highly effective method of contraception from screening and up to 4 weeks after the last dose study drug.

Exclusion criteria

1. History or presence of significant medical or psychological conditions, including substance dependence/abuse, or significant abnormalities in laboratory parameters or vital signs including electrocardiogram (ECG), which in the opinion of the investigator, would compromise the participant's safety or successful participation in the study. As an example, severe anaemia (haemoglobin \< 7.0 g/dL) could be exclusionary due to blood sampling required by the protocol, at the discretion of investigator. 2. Concurrent participation in another interventional study of any kind and repeat randomisation in this study is prohibited. 3. Any participant who has received another study drug as part of a clinical study or a glucagon-like peptide-1 (GLP-1) analogue-containing preparation within the last 30 days or 5 half-lives of the drug (if known; whichever is longer) at the time of Visit 2. 4. Any participant who has received any of the following medications within the specified timeframe prior to the start of the study (Visit 2) * Herbal preparations within 1 week prior to the start of dosing (Visit 4) or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion-naltrexone, phentermine-topiramate, phentermine, lorcaserin) within 30 days (or 5 half-lives of the drug) prior to the start of dosing (Visit 4) * Aspirin (acetylsalicylic acid) at a dose greater than 150 mg once daily and within the last 3 days prior to the start of the run-in period (Visit 2) * Paracetamol (acetaminophen) or paracetamol-containing preparations at a total daily dose of greater than 3000 mg and within the last 3 days prior to the start of the run-in period (Visit 2) * Ascorbic acid (vitamin C) supplements at a total daily dose of greater than 1000 mg and within the last 3 days prior to the start of the run-in period (Visit 2) * Opiates, domperidone, metoclopramide, or other drugs known to alter gastric emptying and within 2 weeks prior to the start of dosing (Visit 4) 5. Severe allergy/hypersensitivity to any of the proposed study treatments or excipients 6. Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus or diabetic ketoacidosis 7. Participants who have undergone a renal transplant 8. Participants with suspicion of acute or subacute renal function deterioration (eg, participants with large fluctuations of creatinine values documented within the 6 months prior to screening) 9. Significant inflammatory bowel disease, gastroparesis, or other severe disease or surgery affecting the upper gastrointestinal (GI) tract including weight-reducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data 10. History of acute or chronic pancreatitis 11. Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: * Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) * Alanine transaminase (ALT) ≥ 3 × ULN * Total bilirubin ≥ 2 × ULN 12. Poorly controlled hypertension defined as: * Systolic blood pressure (BP) \> 180 mm Hg * Diastolic BP ≥ 100 mm Hg Participants who fail BP screening criteria may be considered for 24-hour ambulatory blood pressure monitoring (ABPM) at the discretion of the investigator. Participants who maintain a mean 24-hour systolic BP ≤ 180 or diastolic BP \< 100 mm Hg with a preserved nocturnal dip of \> 15% will be considered eligible 13. Unstable angina pectoris, myocardial infarction, transient ischemic attack or stroke within 3 months prior to screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening 14. Severe congestive heart failure (New York Heart Association Class III or IV) 15. Basal calcitonin level \> 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia 16. History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer 17. Any positive results for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody, and human immunodeficiency virus (HIV) antibody 18. Nephrotic range proteinuria defined as spot urine albumin creatinine ratio (ACR) \> 250 mg/mmol at screening 19. History of substance dependence, alcohol abuse, or excessive alcohol intake (defined as an average weekly intake of \> 21 alcoholic drinks for men or \> 10 alcoholic drinks for women) within 3 years prior to screening, and/or a positive screen for drugs of abuse or alcohol at screening or on Day -5. Participants who use tricyclic antidepressants or benzodiazepines for an established clinical indication may be permitted to enter the study based upon the judgement of the investigator

Design outcomes

Primary

Measure	Time frame	Description
Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test (MMTT) to Day 32	Zero minutes before and 15, 30, 45, 60, 90, 120, 180, and 240 minutes after consumption of the standardised meal on Day -5 (Baseline) and Day 32	The MMTT involved the consumption of a standardised liquid meal (a nutritional supplement containing the components of fat, carbohydrate, and protein, which make up a standard MMTT) within 15 minutes, and timed serial blood samples obtained for measurement of glucose and parameters related to glucose metabolism through 240 minutes after consumption of the standardized meal (with no additional food intake during this time).

Secondary

Measure	Time frame	Description
Number of Participants With Abnormal Vital Signs Reported as TEAEs	Day 1 through Day 60	Number of participants with abnormal vital signs reported as TEAEs is reported. Vital sign measurements were obtained after the participant had rested in the supine position for at least 10 minutes at the recording time. Abnormal vital signs is defined as any abnormal finding in the vital sign parameters (blood pressure, pulse rate, body temperature, and respiratory rate).
Change From Baseline in Postural Blood Pressure	Baseline (Day 1) through Day 32	The change difference is the change from Day 1 to Day 32 in the difference between systolic blood pressure (SBP) or diastolic blood pressure (DBP) values in standing and supine positions. For this outcome measure, participants with difference (standing-supine) in DBP or SBP on Day 1 and Day 32 were analyzed. For few participants either DBP or SBP was recorded eg, standing DBP was not recorded on Day 1 for 2 participants in Placebo arm and 1 participant in MEDI0382 arm; standing SBP was not recorded on Day 32 for a participant in the Placebo arm.
Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs	Day 1 through Day 60	Number of participants with abnormal ECGs reported as TEAEs is reported. Abnormal ECGs is defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, ST-T morphology, and QT intervals from the primary lead of the digital 12-lead ECG.
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Day 1 through Day 60	Number of participants with abnormal clinical laboratory parameters reported as TEAEs is reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of serum chemistry, hematology, and urine.
Number of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESIs)	Day 1 through Day 60	An adverse event of special interest (AESI) was one of scientific and medical interest specific to understanding of the study drug and may require close monitoring and rapid communication by the investigator to the sponsor.
Change From Baseline in Mean 24-hrs Pulse Rate to the End of Each Dosing Level	Day -5 (Baseline) and on Days 5, 12, 19, and 32	Change from baseline in mean 24-hrs pulse rate to the end of each dosing levels: Day 5 for 50 μg; Day 12 for 100 μg, Day 19 for 200 μg, and Day 32 for 300 μg.
Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day -5 (Baseline) and on Days 5, 12, 19, and 32	Change from baseline in mean 24-hrs systolic and diastolic blood pressure to the end of each dosing levels: Day 5 for 50 μg, Day 12 for 100 μg, Day 19 for 200 μg, and Day 32 for 300 μg.
Change From Baseline in Haemoglobin A1c (HbA1c) to Day 32	Day 1 (Baseline) and Day 32	Change from baseline in haemoglobin A1c (HbA1c) is reported.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)	Day 1 through Day 60	An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Change From Baseline in Percentage of Time Spent Within a Target Glucose Range Over a 7-day Period to the Final Week of Treatment	Baseline (Days -8 to -2), Days 5 to 11, Days 12 to 18, Days 19 to 25, and Days 26 to 32 (final week of treatment)	Change from baseline in percentage of time spent within a target glucose range over a 7-day period to the final week of treatment is reported. Target glucose range was considered as 70 mg/dL (3.9 mmol/L) to 180 mg/dL (10 mmol/L).
Percent Change Frome Baseline in Body Weight to Day 33	Day 1 (Baseline) and Day 33	Percent change from baseline in body weight is reported.
Change From Baseline in Absolute Body Weight to Day 33	Day 1 (Baseline) and Day 33	Change from baseline in absolute body weight is reported.
Area Under the Plasma Concentration Time Curve Over a Dosing Duration (AUCτ) of MEDI0382 at 300 μg	Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hrs postdose on Day 32	Area under the plasma concentration time curve over a dosing duration (AUCτ) of MEDI0382 at 300 μg is reported.
Maximum Observed Serum Concentration (Cmax) of MEDI0382 at 300 μg	Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hrs postdose on Day 32	Maximum observed serum concentration (Cmax) of MEDI0382 at 300 μg is reported.
Time to Observed Maximum Serum Concentration (Tmax) of MEDI0382 at 300 μg	Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hrs postdose on Day 32	Time to observed maximum serum concentration (Tmax) of MEDI0382 at 300 μg is reported.
Trough Plasma Concentration (Ctrough) of MEDI0382	Days 1, 5, 12, and 19: Predose; and Day 32: Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hrs postdose (Day 33)	Trough concentration is the lowest concentration reached by a drug before the next dose is administered. Trough plasma concentration of MEDI0382 is reported.
Number of Participants With Positive Anti-drug Antibodies (ADA) Titre to MEDI0382	Pre-dose on Days 1, 12, and 32 and on Day 60	Number of participants with positive Anti-drug antibodies (ADA) Titre to MEDI0382 is reported.
Change From Baseline in Fasting Glucose to Day 32	Day 1 (Baseline) and Day 32	Change from baseline in fasting glucose is reported.

Countries

Germany, United Kingdom

Participant flow

Recruitment details

The study was conducted in the United Kingdom and Germany between 29Jun2018 and 04Feb2019.

Pre-assignment details

A total of 41 participants were randomized to the study.

Participants by arm

Arm	Count
Placebo Participants received subcutaneous dose (SC) of placebo matched to MEDI0382 once daily for 32 days.	20
MEDI0382 Participants received SC dose of MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.	21
Total	41

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Death	0	1

Baseline characteristics

Characteristic	MEDI0382	Total	Placebo
Age, Continuous	71.1 Years STANDARD_DEVIATION 7.4	71.0 Years STANDARD_DEVIATION 6.1	70.9 Years STANDARD_DEVIATION 4.7
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	21 Participants	41 Participants	20 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	1 Participants	1 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	20 Participants	40 Participants	20 Participants
Sex: Female, Male Female	9 Participants	20 Participants	11 Participants
Sex: Female, Male Male	12 Participants	21 Participants	9 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 20	1 / 21
other Total, other adverse events	13 / 20	19 / 21
serious Total, serious adverse events	2 / 20	2 / 21

Outcome results

Primary

Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test (MMTT) to Day 32

The MMTT involved the consumption of a standardised liquid meal (a nutritional supplement containing the components of fat, carbohydrate, and protein, which make up a standard MMTT) within 15 minutes, and timed serial blood samples obtained for measurement of glucose and parameters related to glucose metabolism through 240 minutes after consumption of the standardized meal (with no additional food intake during this time).

Time frame: Zero minutes before and 15, 30, 45, 60, 90, 120, 180, and 240 minutes after consumption of the standardised meal on Day -5 (Baseline) and Day 32

Population: Intent-to-treat (ITT) population included all participants who received any dose of study drug and analyzed according to their randomized treatment group. Here, N signifies only the participants with available data were analyzed for the outcome measure.

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo	Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test (MMTT) to Day 32	3.678 Percent change in plasma glucose
MEDI0382	Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test (MMTT) to Day 32	-26.706 Percent change in plasma glucose

p-value: <0.00190% CI: [-41.27, -19.498]ANCOVA

Secondary

Area Under the Plasma Concentration Time Curve Over a Dosing Duration (AUCτ) of MEDI0382 at 300 μg

Area under the plasma concentration time curve over a dosing duration (AUCτ) of MEDI0382 at 300 μg is reported.

Time frame: Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hrs postdose on Day 32

Population: Pharmacokinetic (PK) population included all participants who received at least 1 dose of study drug and had at least one PK sample collected with a value above the lower limit of quantitation.

Arm	Measure	Value (GEOMETRIC_MEAN)
Placebo	Area Under the Plasma Concentration Time Curve Over a Dosing Duration (AUCτ) of MEDI0382 at 300 μg	285.93 ng.hr/mL

Secondary

Change From Baseline in Absolute Body Weight to Day 33

Change from baseline in absolute body weight is reported.

Time frame: Day 1 (Baseline) and Day 33

Population: An ITT population included all participants who received any dose of study drug and analyzed according to their randomized treatment group. Here, N signifies only the participants with available data were analyzed for the outcome measure.

Arm	Measure	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Absolute Body Weight to Day 33	-0.15 Kg	Standard Deviation 1.84
MEDI0382	Change From Baseline in Absolute Body Weight to Day 33	-3.39 Kg	Standard Deviation 2.16

Secondary

Change From Baseline in Fasting Glucose to Day 32

Change from baseline in fasting glucose is reported.

Time frame: Day 1 (Baseline) and Day 32

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo	Change From Baseline in Fasting Glucose to Day 32	0.60 mg/dL
MEDI0382	Change From Baseline in Fasting Glucose to Day 32	-19.55 mg/dL

Secondary

Change From Baseline in Haemoglobin A1c (HbA1c) to Day 32

Change from baseline in haemoglobin A1c (HbA1c) is reported.

Time frame: Day 1 (Baseline) and Day 32

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo	Change From Baseline in Haemoglobin A1c (HbA1c) to Day 32	0.01 Percent
MEDI0382	Change From Baseline in Haemoglobin A1c (HbA1c) to Day 32	-0.65 Percent

Secondary

Change From Baseline in Mean 24-hrs Pulse Rate to the End of Each Dosing Level

Change from baseline in mean 24-hrs pulse rate to the end of each dosing levels: Day 5 for 50 μg; Day 12 for 100 μg, Day 19 for 200 μg, and Day 32 for 300 μg.

Time frame: Day -5 (Baseline) and on Days 5, 12, 19, and 32

Population: As-treated population included all participants who received any dose of study drug and analyzed according to the treatment they actually received. Here, n signifies only the participants with available data were analyzed for the specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Mean 24-hrs Pulse Rate to the End of Each Dosing Level	Day 5	-0.73 Beats/min	Standard Deviation 4.13
Placebo	Change From Baseline in Mean 24-hrs Pulse Rate to the End of Each Dosing Level	Day 12	1.04 Beats/min	Standard Deviation 5.07
Placebo	Change From Baseline in Mean 24-hrs Pulse Rate to the End of Each Dosing Level	Day 19	1.32 Beats/min	Standard Deviation 5.28
Placebo	Change From Baseline in Mean 24-hrs Pulse Rate to the End of Each Dosing Level	Day 32	-0.92 Beats/min	Standard Deviation 4.51
MEDI0382	Change From Baseline in Mean 24-hrs Pulse Rate to the End of Each Dosing Level	Day 32	11.85 Beats/min	Standard Deviation 8.82
MEDI0382	Change From Baseline in Mean 24-hrs Pulse Rate to the End of Each Dosing Level	Day 5	6.40 Beats/min	Standard Deviation 5.53
MEDI0382	Change From Baseline in Mean 24-hrs Pulse Rate to the End of Each Dosing Level	Day 19	12.72 Beats/min	Standard Deviation 8.93
MEDI0382	Change From Baseline in Mean 24-hrs Pulse Rate to the End of Each Dosing Level	Day 12	9.01 Beats/min	Standard Deviation 7.73

Secondary

Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level

Change from baseline in mean 24-hrs systolic and diastolic blood pressure to the end of each dosing levels: Day 5 for 50 μg, Day 12 for 100 μg, Day 19 for 200 μg, and Day 32 for 300 μg.

Time frame: Day -5 (Baseline) and on Days 5, 12, 19, and 32

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 5: Systolic Blood Pressure	-3.11 mmHg	Standard Deviation 9.97
Placebo	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 12: Systolic Blood Pressure	-2.67 mmHg	Standard Deviation 12.3
Placebo	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 19: Systolic Blood Pressure	-3.56 mmHg	Standard Deviation 10.15
Placebo	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 32: Systolic Blood Pressure	2.21 mmHg	Standard Deviation 7.24
Placebo	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 5: Diastolic Blood Pressure	-0.07 mmHg	Standard Deviation 3.19
Placebo	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 12: Diastolic Blood Pressure	-0.55 mmHg	Standard Deviation 5.17
Placebo	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 19: Diastolic Blood Pressure	-0.44 mmHg	Standard Deviation 3.85
Placebo	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 32: Diastolic Blood Pressure	1.84 mmHg	Standard Deviation 1.79
MEDI0382	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 32: Diastolic Blood Pressure	2.54 mmHg	Standard Deviation 5.34
MEDI0382	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 5: Systolic Blood Pressure	-1.69 mmHg	Standard Deviation 9.06
MEDI0382	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 5: Diastolic Blood Pressure	1.15 mmHg	Standard Deviation 3.64
MEDI0382	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 12: Systolic Blood Pressure	-4.34 mmHg	Standard Deviation 11.46
MEDI0382	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 19: Diastolic Blood Pressure	0.76 mmHg	Standard Deviation 3.75
MEDI0382	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 19: Systolic Blood Pressure	-4.72 mmHg	Standard Deviation 11.65
MEDI0382	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 12: Diastolic Blood Pressure	1.28 mmHg	Standard Deviation 5.22
MEDI0382	Change From Baseline in Mean 24-hrs Systolic and Diastolic Blood Pressure to the End of Each Dosing Level	Day 32: Systolic Blood Pressure	-1.15 mmHg	Standard Deviation 18.43

Secondary

Change From Baseline in Percentage of Time Spent Within a Target Glucose Range Over a 7-day Period to the Final Week of Treatment

Change from baseline in percentage of time spent within a target glucose range over a 7-day period to the final week of treatment is reported. Target glucose range was considered as 70 mg/dL (3.9 mmol/L) to 180 mg/dL (10 mmol/L).

Time frame: Baseline (Days -8 to -2), Days 5 to 11, Days 12 to 18, Days 19 to 25, and Days 26 to 32 (final week of treatment)

Population: An ITT population included all participants who received any dose of study drug and analyzed according to their randomized treatment group. Here, n signifies only the participants with available data were analyzed for the specified time points.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo	Change From Baseline in Percentage of Time Spent Within a Target Glucose Range Over a 7-day Period to the Final Week of Treatment	Days 5 - 11	-10.49 Percentage of time
Placebo	Change From Baseline in Percentage of Time Spent Within a Target Glucose Range Over a 7-day Period to the Final Week of Treatment	Days 12 - 18	-5.34 Percentage of time
Placebo	Change From Baseline in Percentage of Time Spent Within a Target Glucose Range Over a 7-day Period to the Final Week of Treatment	Days 19 - 25	-16.05 Percentage of time
Placebo	Change From Baseline in Percentage of Time Spent Within a Target Glucose Range Over a 7-day Period to the Final Week of Treatment	Days 26 - 32	-21.23 Percentage of time
MEDI0382	Change From Baseline in Percentage of Time Spent Within a Target Glucose Range Over a 7-day Period to the Final Week of Treatment	Days 26 - 32	14.79 Percentage of time
MEDI0382	Change From Baseline in Percentage of Time Spent Within a Target Glucose Range Over a 7-day Period to the Final Week of Treatment	Days 5 - 11	12.25 Percentage of time
MEDI0382	Change From Baseline in Percentage of Time Spent Within a Target Glucose Range Over a 7-day Period to the Final Week of Treatment	Days 19 - 25	19.18 Percentage of time
MEDI0382	Change From Baseline in Percentage of Time Spent Within a Target Glucose Range Over a 7-day Period to the Final Week of Treatment	Days 12 - 18	15.62 Percentage of time

Secondary

Change From Baseline in Postural Blood Pressure

The change difference is the change from Day 1 to Day 32 in the difference between systolic blood pressure (SBP) or diastolic blood pressure (DBP) values in standing and supine positions. For this outcome measure, participants with difference (standing-supine) in DBP or SBP on Day 1 and Day 32 were analyzed. For few participants either DBP or SBP was recorded eg, standing DBP was not recorded on Day 1 for 2 participants in Placebo arm and 1 participant in MEDI0382 arm; standing SBP was not recorded on Day 32 for a participant in the Placebo arm.

Time frame: Baseline (Day 1) through Day 32

Population: As-treated population included all participants who received any dose of study drug and analyzed according to the treatment they actually received. Participants with difference (standing-supine) in DBP or SBP on Day 1 and the participants with difference (standing-supine) in DBP or SBP on Day 32 were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Postural Blood Pressure	Systolic Blood Pressure	0.1 mmHg	Standard Deviation 9.3
Placebo	Change From Baseline in Postural Blood Pressure	Diastolic Blood Pressure	1.8 mmHg	Standard Deviation 6.3
MEDI0382	Change From Baseline in Postural Blood Pressure	Systolic Blood Pressure	8.9 mmHg	Standard Deviation 14.2
MEDI0382	Change From Baseline in Postural Blood Pressure	Diastolic Blood Pressure	0.8 mmHg	Standard Deviation 5.2

Secondary

Maximum Observed Serum Concentration (Cmax) of MEDI0382 at 300 μg

Maximum observed serum concentration (Cmax) of MEDI0382 at 300 μg is reported.

Time frame: Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hrs postdose on Day 32

Population: The PK population included all participants who received at least 1 dose of study drug and had at least one PK sample collected with a value above the lower limit of quantitation.

Arm	Measure	Value (GEOMETRIC_MEAN)
Placebo	Maximum Observed Serum Concentration (Cmax) of MEDI0382 at 300 μg	16.93 ng/mL

Secondary

Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

Number of participants with abnormal clinical laboratory parameters reported as TEAEs is reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of serum chemistry, hematology, and urine.

Time frame: Day 1 through Day 60